Morningside Ventures has led a $30m series A round for Emory University spinout Meissa Vaccines, a current resident at Johnson & Johnsons’ JLabs incubator.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The gum disease vaccine developer has spun out of University of Melbourne with series A funding from investors including CSL.

Gum disease vaccine developer Denteric has spun out of Melbourne with series A capital from the institution, the Biomedical Translation Fund and CSL.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Aprea Therapeutics, a Karolinska Institute spinout, is set to raise as much as $92m from an offering that would bank Karolinska Development a return of up to $8m.

The microbiome drug developer took its total series C funding to more than $62m, adding $16.6m from investors including Symbiosis, JSR and Bristol-Myers Squibb.

Frequency Therapeutics, a regenerative medicine developer advancing MIT and Harvard research, has set the range for an initial public offering that will raise $107m if it floats at the high end.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Curamir Therapeutics, a cancer therapeutics developer exploiting Suny research into microRNA, has made its formal debut with $10m of series A funding.